...
首页> 外文期刊>Clinical & developmental immunology. >Humoral Autoimmune Responses to Insulin-Like Growth Factor II mRNA-Binding Proteins IMP1 and p62/IMP2 in Ovarian Cancer
【24h】

Humoral Autoimmune Responses to Insulin-Like Growth Factor II mRNA-Binding Proteins IMP1 and p62/IMP2 in Ovarian Cancer

机译:卵巢癌对胰岛素样生长因子II mRNA结合蛋白IMP1和p62 / IMP2的体液自身免疫反应。

获取原文
获取原文并翻译 | 示例

摘要

Ovarian cancer is one of the leading causes of cancer-related deaths among women. There is an urgent need of better approaches for the identification of appropriate biomarkers in the early detection of ovarian cancer. The aim of this study was to elucidate the significance of autoantibodies against insulin-like growth factor II mRNA-binding proteins (IMPs) in patients with ovarian cancer. In this study, autoantibody responses to two members (IMP1 and p62/IMP2) of IMPs were evaluated by enzyme-linked immunosorbent assay (ELISA), western blotting, and indirect immunofluorescence assay in sera from patients with ovarian cancer and normal human individuals. The results have demonstrated that both IMP1 and p62/IMP2 can induce relatively higher frequency of autoantibody responses in patients with ovarian cancer (26.5% and 29.4%) compared to normal individuals (P < 0.01). Our preliminary data suggest that IMP1 and p62/IMP2 can stimulate autoimmune responses in ovarian cancer, and anti-IMP1 and anti-p62/IMP2 autoantibodies could be used as potential biomarkers in immunodiagnosis of ovarian cancer.
机译:卵巢癌是女性与癌症相关的死亡的主要原因之一。在卵巢癌的早期检测中,迫切需要更好的方法来鉴定合适的生物标记。这项研究的目的是阐明在卵巢癌患者中针对胰岛素样生长因子II mRNA结合蛋白(IMPs)的自身抗体的重要性。在这项研究中,通过酶联免疫吸附测定(ELISA),蛋白质印迹和间接免疫荧光测定评估了卵巢癌患者和正常人血清中对IMPs的两个成员(IMP1和p62 / IMP2)的自身抗体反应。结果表明,与正常个体相比,IMP1和p62 / IMP2均可在卵巢癌患者中诱导相对较高的自身抗体应答频率(26.5%和29.4%)(P <0.01)。我们的初步数据表明,IMP1和p62 / IMP2可以刺激卵巢癌的自身免疫反应,而抗IMP1和抗p62 / IMP2自身抗体可以用作卵巢癌免疫诊断的潜在生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号